Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly

Pharmacogenomics

Volumn 10, Issue 4, 2009, Pages 541-547

  Bijl, Monique J ^a   Luijendijk, Hendrika J ^a,b   van den Berg, Julia F ^a   Visser, Loes E ^a   van Schaik, Ron H N ^a   Hofman, Albert ^a   Vulto, Arnold G ^a   van Gelder, Teun ^a   Tiemeier, Henning ^a   Stricker, Bruno H Ch ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Parnassia BAVO Group   (Netherlands)

^c Inspectorate for Health Care   (Netherlands)

Author keywords

5 Methoxytryptamine; Anxiety; CYP2D6; Depression; Serotonin

Indexed keywords

5 METHOXYTRYPTAMINE; CYTOCHROME P450 2D6; SEROTONIN;

AGED; ANXIETY DISORDER; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DNA POLYMORPHISM; DYSTHYMIA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR DEPRESSION; MALE; PHARMACOGENOMICS; AGING; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; STATISTICAL MODEL;

AGED; AGING; ANXIETY DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; DEPRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; POLYMORPHISM, GENETIC;

EID: 66849112021     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.9     Document Type: Article

References (26)

1. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2D6 ( CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13 (2005).
2. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002).
3. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS: The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008).
4. Bertilsson L, Dahl ML, Sjoqvist F et al.: Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341, 63 (1993).
5. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA 90, 11825-11829 (1993).
6. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M: Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11, 237-245 (2001).
7. Gervasini G, Carrillo JA, Benitez J: Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin. Pharmacokinet. 43, 693-706 (2004).
8. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D: Debrisoquine hydroxylation polymorphism and personality. Lancet 1, 555 (1989).
9. Llerena. A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L: Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87, 23-28 (1993).
10. Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA: Association between cytochrome P450 2D6 genotype and harm avoidance. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 127, 90-93 (2004).
11. Gan SH, Ismail R, Wan Adnan WA, Zulmi W, Kumaraswamy N, Larmie ET: Relationship between Type A and B personality and debrisoquine hydroxylation capacity. Br. J. Clin. Pharmacol. 57, 785-789 (2004).
12. Kirchheiner J, Lang U, Stamm T, Sander T, Gallinat J: Association of CYP2D6 genotypes and personality traits in healthy individuals. J. Clin. Psychopharmacol. 26, 440-442 (2006).
13. Ozdemir V, Gunes A, Dahl ML, Scordo MG, Williams-Jones B, Someya T: Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness? Pharmacogenomics 7, 1199-1210 (2006).
14. Enns MW, Cox BJ: Personality dimensions and depression: review and commentary. Can. J. Psychiatry 42, 274-284 (1997).
15. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13, 173-181 (2003).
16. Kirchheiner J, Henckel HB, Franke I, et al.: Impact of the CYP2D6 ultra-rapid merabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet. Genomics 15, 579-587 (2005).
17. de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ: Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am. J. Psychiatry 155, 1278-1280 (1998).
18. Rau T, Wohlleben G, Wuttke H et al.: CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin. Pharmacol. Ther. 75, 386-393 (2004).
19. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA: Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur. J. Epidemiol. 7, 403-422 (1991).
20. Hoffman A, Breteler MM, van Duijn CM et al.: The Rotterdam Study: objectives and design update. Eur. J. Epidemiol. 22, 819-829 (2007).
21. Radloff L: The CES-D scale: a self-report depression scale for research in the general population. Appl. Psychol. Meas. 1, 385-401 (1977).
22. Luijendijk HJ, van den Berg J, Dekker MJHJ et al.: Incidence and recurrence of late-life depression. Arch. Gen. Psychiatry 65(12), 1394-1401 (2008).
23. Wittchen HU, Lachner G, Wunderlich U, Pfister H: Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc. Psychiatry Pychiatr. Epidemiol. 33, 568-578 (1998).
24. Bijl MJ, Visser LE, Hofman A et al.: Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br. J. Clin. Pharmacol. 65, 558-564 (2008).
25. Yu AM, Idle JR, Gonzalez FJ: Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab. Rev. 36, 243-277 (2004).
26. Hiroi T, Imaoka S, Funae Y: Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 249, 838-843 (1998).